Osteoblastgenic and Osteogenic Effects of KY-273 with CDK8/19 Inhibitory Activity in Bone Marrow Mesenchymal Stem Cells and Female Rats

In conclusion, KY-273 has cortical-bone-selective osteogenic effects by osteoblastogenesis via CDK8/19 inhibition in ovaries-intact and ovariectomized rats, and is an orally active drug candidate for bone diseases such as osteoporosis in monotherapy and combination therapy.PMID:38508765 | DOI:10.1248/bpb.b23-00834

Source: Biological and Pharmaceutical Bulletin - March 20, 2024 Category: Drugs & Pharmacology Authors: Megumi Yamamoto Yui Shibata Yuma Ito Masaki Fukui Hikaru Kioka Yoshimichi Shoji Tatsuya Kitao Hiroaki Shirahase Eiichi Hinoi Source Type: research